Mark A. Varney

5.7k total citations · 1 hit paper
85 papers, 4.6k citations indexed

About

Mark A. Varney is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Cognitive Neuroscience. According to data from OpenAlex, Mark A. Varney has authored 85 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Cellular and Molecular Neuroscience, 45 papers in Molecular Biology and 13 papers in Cognitive Neuroscience. Recurrent topics in Mark A. Varney's work include Neuroscience and Neuropharmacology Research (60 papers), Receptor Mechanisms and Signaling (31 papers) and Neurotransmitter Receptor Influence on Behavior (23 papers). Mark A. Varney is often cited by papers focused on Neuroscience and Neuropharmacology Research (60 papers), Receptor Mechanisms and Signaling (31 papers) and Neurotransmitter Receptor Influence on Behavior (23 papers). Mark A. Varney collaborates with scholars based in United States, United Kingdom and Netherlands. Mark A. Varney's co-authors include Linda J. Bristow, Sara Rao, Nicholas D. P. Cosford, Adrian Newman‐Tancredi, Jesse Brodkin, Daniel S. Lorrain, Edwin C. Johnson, Christopher Baccei, Lida Tehrani and Stephen D. Hess and has published in prestigious journals such as The Journal of Comparative Neurology, Analytical Biochemistry and Scientific Reports.

In The Last Decade

Mark A. Varney

84 papers receiving 4.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist

1999 628 citations F. Gasparini, Peter J. Flor et al. Neuropharmacology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Mark A. Varney	3.5k	2.3k	737	614	395	85	4.6k
Xavier Langlois	2.3k 0.7×	2.1k 0.9×	397 0.5×	510 0.8×	435 1.1×	104	4.2k
James N.C. Kew	3.5k 1.0×	3.0k 1.3×	712 1.0×	560 0.9×	367 0.9×	71	4.8k
David L. McKinzie	4.0k 1.2×	3.1k 1.3×	852 1.2×	581 0.9×	445 1.1×	100	5.6k
Vincent Mutel	3.3k 1.0×	2.8k 1.2×	612 0.8×	366 0.6×	276 0.7×	85	4.6k
Wolfgang Froestl	5.5k 1.6×	4.3k 1.9×	672 0.9×	1.0k 1.7×	376 1.0×	92	7.3k
Carrie K. Jones	4.0k 1.1×	3.9k 1.7×	705 1.0×	427 0.7×	472 1.2×	161	5.8k
Cyrille Sur	3.4k 1.0×	2.5k 1.1×	857 1.2×	1.0k 1.7×	503 1.3×	90	5.5k
David Bleakman	4.8k 1.4×	3.5k 1.5×	1.1k 1.5×	1.0k 1.7×	476 1.2×	94	6.5k
Guido Maura	2.6k 0.8×	2.1k 0.9×	504 0.7×	420 0.7×	303 0.8×	128	4.0k
Francesco Impagnatiello	1.8k 0.5×	1.7k 0.8×	554 0.8×	479 0.8×	286 0.7×	51	4.4k

Countries citing papers authored by Mark A. Varney

Since Specialization

Citations

This map shows the geographic impact of Mark A. Varney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Varney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Varney more than expected).

Fields of papers citing papers by Mark A. Varney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Varney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Varney. The network helps show where Mark A. Varney may publish in the future.

Co-authorship network of co-authors of Mark A. Varney

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Varney. A scholar is included among the top collaborators of Mark A. Varney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Varney. Mark A. Varney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xin, Tao, et al.. (2025). Acute administration of NLX-101, a Serotonin 1A receptor agonist, improves auditory temporal processing during development in a mouse model of Fragile X Syndrome. Journal of Neurodevelopmental Disorders. 17(1). 1–1. 1 indexed citations

Depoortère, Ronan, Andrew C. McCreary, Benjamin Vidal, et al.. (2024). Pharmacodynamic, pharmacokinetic and rat brain receptor occupancy profile of NLX-112, a highly selective 5-HT1A receptor biased agonist. Naunyn-Schmiedeberg s Archives of Pharmacology. 398(1). 991–1002. 1 indexed citations

Depoortère, Ronan, Jack Bergman, Patrick M. Beardsley, et al.. (2022). NLX-112, a highly selective 5-HT1A receptor biased agonist, does not exhibit misuse potential in male rats or macaques. Neuropharmacology. 210. 109025–109025. 1 indexed citations

Newman‐Tancredi, Adrian, et al.. (2022). Acute and Repeated Administration of NLX-101, a Selective Serotonin-1A Receptor Biased Agonist, Reduces Audiogenic Seizures in Developing Fmr1 Knockout Mice. Neuroscience. 509. 113–124. 8 indexed citations

Varney, Mark A., et al.. (2020). ACNP 59th Annual Meeting: Poster Session III. Neuropsychopharmacology. 45(S1). 278–382. 3 indexed citations

Śniecikowska, Joanna, Monika Głuch‐Lutwin, Adam Bucki, et al.. (2019). Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT_1A Receptor-Biased Agonists with Robust Antidepressant-like Activity. Journal of Medicinal Chemistry. 62(5). 2750–2771. 29 indexed citations

Soares, Lígia Mendes, Erika Meyer, Humberto Milani, et al.. (2019). Activation of 5-HT1A postsynaptic receptors by NLX-101 results in functional recovery and an increase in neuroplasticity in mice with brain ischemia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 99. 109832–109832. 44 indexed citations

Iderberg, Hanna, Andrew C. McCreary, Mark A. Varney, M. Angela Cenci, & Adrian Newman‐Tancredi. (2015). Activity of serotonin 5-HT1A receptor ‘biased agonists’ in rat models of Parkinson's disease and l-DOPA-induced dyskinesia. Neuropharmacology. 93. 52–67. 57 indexed citations

Mueller, Rudolf, Stanisław Rachwał, Steven Lee, et al.. (2011). Benzotriazinone and benzopyrimidinone derivatives as potent positive allosteric AMPA receptor modulators. Bioorganic & Medicinal Chemistry Letters. 21(20). 6170–6175. 17 indexed citations

10.

Hopkins, Seth C., J. Brian Nofsinger, M.S. Allen, Patrick Koch, & Mark A. Varney. (2009). In vivosaturation binding of GABA‐A receptor ligands to estimate receptor occupancy using liquid chromatography/tandem mass spectrometry. Biopharmaceutics & Drug Disposition. 30(1). 9–20. 4 indexed citations

11.

Brodkin, Jesse, Jeffery J. Anderson, Lida Tehrani, et al.. (2004). The Behavioral Profile of the Potent and Selective mGlu5 Receptor Antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in Rodent Models of Anxiety. Neuropsychopharmacology. 29(11). 1971–1979. 137 indexed citations

12.

Bradbury, Margaret, et al.. (2003). Metabotropic glutamate receptor 5 antagonist-induced stimulation of hypothalamic–pituitary–adrenal axis activity: interaction with serotonergic systems. Neuropharmacology. 44(5). 562–572. 43 indexed citations

13.

Varney, Mark A., Fen‐Fen Lin, Christine Jachec, et al.. (2003). Stable Expression of Human NMDA Receptors in Cultured Mammalian Cells. Humana Press eBooks. 128. 43–59. 4 indexed citations

14.

Schaffhauser, Hervé, Blake A. Rowe, Laura E. Chavez-Noriega, et al.. (2003). Pharmacological Characterization and Identification of Amino Acids Involved in the Positive Modulation of Metabotropic Glutamate Receptor Subtype 2. Molecular Pharmacology. 64(4). 798–810. 137 indexed citations

15.

Anderson, Jeffery J., Margaret Bradbury, Deborah F. Chapman, et al.. (2003). In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine). European Journal of Pharmacology. 473(1). 35–40. 124 indexed citations

16.

Veliçelebi, Gönül, Kenneth A. Stauderman, Mark A. Varney, et al.. (1999). [2] Fluorescence techniques for measuring ion channel activity. Methods in enzymology on CD-ROM/Methods in enzymology. 294. 20–47. 23 indexed citations

17.

Gasparini, F., Valeria Bruno, Giuseppe Battaglia, et al.. (1999). (R, S)-4-Phosphonophenylglycine, a Potent and Selective Group III Metabotropic Glutamate Receptor Agonist, Is Anticonvulsive and Neuroprotective In Vivo. Journal of Pharmacology and Experimental Therapeutics. 289(3). 1678–1687. 143 indexed citations

18.

Varney, Mark A., Sara Rao, Christine Jachec, et al.. (1998). Pharmacological Characterization of the Human Ionotropic Glutamate Receptor Subtype GluR3 Stably Expressed in Mammalian Cells. Journal of Pharmacology and Experimental Therapeutics. 285(1). 358–370. 17 indexed citations

19.

Varney, Mark A., Christine Jachec, C Deal, et al.. (1996). Stable expression and characterization of recombinant human heteromeric N-methyl-D-aspartate receptor subtypes NMDAR1A/2A and NMDAR1A/2B in mammalian cells.. Journal of Pharmacology and Experimental Therapeutics. 279(1). 367–378. 43 indexed citations

20.

Daggett, Lorrie P., Aida Sacaan, M. Akong, et al.. (1995). Molecular and functional characterization of recombinant human metabotropic glutamate receptor subtype 5. Neuropharmacology. 34(8). 871–886. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact